Use

Oncogenic mutations in MYD88, particularly the L265P mutation, are driver mutations in various B‑cell lymphomas. The L265P mutation is present in approximately 90% of Waldenström macroglobulinemia and IgM‑expressing lymphoplasmacytic lymphoma (LPL). It occurs less frequently in other systemic CD5‑negative B‑cell lymphoproliferative disorders, including atypical chronic lymphocytic leukemia, nodal marginal zone lymphoma, splenic MZL, and MALT‑type MZL. This next‑generation sequencing (NGS) assay detects clinically significant MYD88 mutations including L265P, aiding diagnosis of Waldenström macroglobulinemia or IgM‑expressing LPL and patient stratification/subclassification.